LEXINGTON, Mass.--(BUSINESS WIRE)--May 16, 2019--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has
initiated a second open label clinical trial to evaluate once-daily
compared to twice-daily oral dosing of CTP-543 in patients with alopecia
areata. Patients in the trial will be randomized to receive either 12 mg
twice-daily or 24 mg once-daily of CTP-543 over a 24 week treatment
This new dose regimen trial is designed to complement the first open
label trial initiated by Concert in March 2019, which is ongoing in
patients randomized to receive either 8 mg twice-daily or 16 mg
once-daily of CTP-543 over a 24 week treatment period. These two trials
are designed to inform on the optimal dosing regimen for CTP-543 for
future clinical trials.
“Our aim is to optimize the dosing regimen for CTP-543, so that we can
best meet the needs of patients with this autoimmune disease for which
there are currently no FDA-approved treatments,” said James V. Cassella,
Ph.D., Chief Development Officer of Concert Pharmaceuticals. “We are
pleased that our CTP-543 clinical efforts are helping to lead the way to
develop a new treatment for alopecia areata.”
The open label trial will enroll approximately 60 patients with
moderate-to-severe alopecia areata in the United States and Canada. The
trial will measure the relative change in Severity of Alopecia Tool
(SALT) score between Week 24 and baseline. The trial is expected to be
completed in the first half of 2020. All patients who complete 24 weeks
of treatment will be eligible to enroll into an open label extension
study of CTP-543. Additional information about the trial (NCT03941548)
is available on www.clinicaltrials.gov.
About CTP-543 Interim Phase 2 Results
late-breaking clinical trials session at the American Academy of
Dermatology (AAD) Annual Meeting on March 2, 2019, the Company presented
interim results from an ongoing Phase 2 trial. At 24 weeks, patients
treated with an 8 mg twice-daily dose of CTP-543 met the primary
efficacy endpoint with a statistically significant difference compared
to placebo (p <0.001). The primary outcome measure was the proportion of
patients with a ≥ 50% relative reduction in their overall SALT score
between Week 24 and baseline. As reported, CTP-543 was generally well
tolerated and there were no serious adverse events reported. Dosing in
an additional cohort receiving a 12 mg twice-daily dose of CTP-543
compared to placebo in the Phase 2 trial is currently ongoing.
Additional information about the CTP-543 Phase 2 results is available in
Presentations section of Company’s website.
CTP-543 was discovered by applying Concert's
deuterium chemistry technology to modify ruxolitinib, a drug which
inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially
available under the name Jakafi® in the United States for the treatment
of certain blood disorders. Deuterium modification of ruxolitinib was
found to alter its human pharmacokinetics in ways which may enhance its
use as a treatment for alopecia areata. The U.S. Food and Drug
Administration (FDA) has granted Fast Track designation for CTP-543.
About Alopecia Areata
Alopecia areata is an autoimmune
disease that results in partial or complete loss of hair on the scalp
and body that may affect up to 650,000 Americans at any given time1.
The scalp is the most commonly affected area, but any hair-bearing site
can be affected alone or together with the scalp. Onset of the disease
can occur throughout life with the majority of patients initially having
symptoms by age 40. It is believed to equally affect both women and men.
Alopecia areata can be associated with serious psychological
consequences, including anxiety and depression. There are currently no
drugs approved by the FDA for the treatment of alopecia areata.
Following the FDA’s Patient-Focused Drug Development meeting held in
September 2017 on alopecia areata, the FDA summarized the input shared
by patients and patient representatives in a Voice
of the Patient report. Additional information on the PFDDI is
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to treat serious diseases and address unmet patient
needs. The Company’s approach starts with previously studied compounds,
including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy.
Concert’s pipeline of
innovative medicines targets autoimmune diseases and central nervous
systems (CNS) disorders. For more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.
Cautionary Note on Forward Looking Statements
in this press release about our future expectations, plans and
prospects, including statements about our expectations for clinical
development of CTP-543, and other statements containing the words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “would,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the
initiation of future clinical trials, whether preliminary results from a
clinical trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory approvals,
availability of funding sufficient for our foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other
factors discussed in the “Risk Factors” section of our most recent
Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission and in other filings that we make with the Securities and
Exchange Commission. In addition, any forward-looking statements
included in this press release represent our views only as of the date
of this release and should not be relied upon as representing our views
as of any subsequent date. We specifically disclaim any obligation to
update any forward-looking statements included in this press release.
1 Fricke M. Epidemiology and Burden of alopecia areata: a
systemic review. Clinical, Cosmetic and Investigational Dermatology.
2015; Vol 8. 397-403.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Jakafi® is a registered trademark of Incyte Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005063/en/
Source: Concert Pharmaceuticals, Inc.
Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
The Yates Network